Published online Mar 27, 2014. doi: 10.4254/wjh.v6.i3.114
Revised: December 10, 2013
Accepted: February 16, 2014
Published online: March 27, 2014
Core tip: Fatty liver is associated with increased risk for the development of cirrhosis and hepatocellular carcinoma. Thyroid hormones have some potentially therapeutic actions by binding to specific nuclear receptors [thyroid hormone receptors (TR)] of which the TRβ isoform is liver specific and a putative target for the treatment of dyslipidemia and fatty liver. This review provides (1) an overview of the action of T3 on lipid metabolism and (2) an update concerning the administration of TRβ selective thyromimetics (GC-1 and MB07811), as well as of 3,5-diiodo-L-thyronine and its novel functional analogue TRC150094 in animal models of overweight and fatty liver.